Nanovaccine for immunotherapy and reduced hepatitis-B virus in humanized model

Figures & data

Figure 1. Schematic representation of preparation of chimeric mice and component of bone marrow cells.

Table 1. Chimera mice groups and vaccination schedule.

S. No.	Group	Vaccination
1.	Group I	Bone marrow transplant + PBMC--- vaccine
2.	Group II	Bone marrow transplant + PBMC + TT --- saline
3.	Group III	Bone marrow transplant + PBMC + TT --- Vaccine

Figure 2. Systemic diagram of nanoparticles by double emulsion solvent evaporation method.

Table 2. Serological data of PBMCs donors/patients suffering from hepatitis B virus.

Anti-HBs(mU/ml)	Anti-HBc	Anti-Hbe	HBsAg	HBcAg	HBeAg	HBV-DNA(mIU/ml)	AST/ALT (U/L)	Bilirubin(mg/dl)	ProthrombinTime (Sec.)	Albumin(g/dl)
– (−ve)	– (−ve)	0.04 (+Ve)	– (+Ve)	– (+Ve)	0.27 (−Ve)	2186 (+Ve)	<1	0.2	7–8	4.4

Figure 3. (A) Levels of human immunoglobulins (IgG) and (B) cytokine (IFN-Y) in sera of chimeric mice transplanted with PBMCs of HBV-immunized carriers. Balb/c chimeric mice were transplanted with PBMCs and vaccinated with HBsAg loaded polymeric particles or TT. Sera were collected at day first and 18 days.

Figure 4. (A) HBsAg and (B) Anti-HBs antibody levels in serum of chimeric mice transplanted with PBMCs of HBV-immunized carriers. Balb/c/scid chimeric mice were transplanted with PBMCs and vaccinated the same day with HBsAg loaded polymeric particles. Sera were collected at the indicated time points and assessed.

Figure 5. HBcAg expression in the liver on (A) day 1 and (B) days 18.

Figure 6. Viremia concentration of sera of chimeric mice transplanted with PBMCs of HBV-immunized carriers. Balb/c chimeric mice were transplanted with PBMCs and vaccinated with HBsAg-loaded polymeric particles or TT. Sera were collected at days first, 6, 12 and 18.